Background: Anti-Mϋllerian hormone (AMH) plays an important role regulating ovarian sensitivity to follicle-stimulating hormone and luteinizing hormone in folliculogenesis. Anti-Mϋllerian hormone is well established as a biomarker of ovarian reserve but may also have utility in predicting pregnancy outcomes. Few studies have described AMH levels in pregnancy and, among those that have, most have used cross-sectional study designs and are limited to participants seeking fertility treatment. Our aim was to analyze AMH longitudinally in low-risk pregnancies.
gonadotropins, 6 and in gene expression, leading to production of ovarian steroids. 6, 7 Anti-Müllerian hormone is a well-described biomarker of ovarian reserve and has been used to predict age-at-menopause 8, 9 and primary ovarian insufficiency. 10, 11 Studies suggest that AMH levels have minimal variability across the menstrual cycle. [12] [13] [14] Influences on AMH, other than age, 12, 15 include use of oral contraceptives 16, 17 and smoking status. 13 Although well established as a biomarker of fecundability, few studies have described AMH levels during pregnancy, and there is some uncertainty regarding how levels vary across gestation in healthy pregnancies. The limited studies of AMH in pregnancy include crosssectional comparisons, 18 assessment in women seeking fertility treatment, 19 assessment in women with gestational diabetes, 20 and evaluation in healthy women by using biospecimens collected once each trimester. 21 To further evaluate variation in AMH levels over gestation and between women in pregnancy, we used data from a prospective pregnancy study with longitudinal biospecimen collection from women with singleton normal pregnancies. Characterization of the variability of AMH levels during uncomplicated pregnancy is an important step toward assessment of the association of AMH with adverse pregnancy outcomes.
2 | METHODS
| Study sample
Women in our sample (n = 30) were recruited as part of the Patterns 
| AMH measurement
Blood samples were collected at prenatal care visits via venipuncture.
Purple top BD Vacutainer tubes with K2EDTA additives were used to collect 10-mL aliquots of whole blood and put in ice until processing.
Blood samples were cold centrifuged, and plasma was aliquoted into 0.5-mL samples and stored at −80°C. Samples were processed within 2 hours of collection. Anti-Müllerian hormone was measured by using an ultra-sensitive ELISA from ANSH Labs (picoAMH kit, catalog number AL-124, Webster, TX) at the Boston Children's Hospital, completed in accordance with the manufacturer's instructions. Percent variation for repeated ELISA samples was between 3.2% and 5.8%. between women relative to temporal variation over gestation, we estimated intraclass correlation coefficients. In addition, we used mixed models of natural log transformed AMH to evaluate log-linear trends over gestation. For these models, a random intercept was tested to evaluate individual variability in baseline AMH. All statistical analyses were carried out by using SAS software v.9.4 (SAS Institute Inc., Cary, NC).
| Statistical analyses
3 | RESULTS
| Participant characteristics
Of the 30 study participants, 29 women completed all 5 scheduled visits (97%), and the remaining participant completed 4 visits. Thus, overall compliance with the study protocol was high, with a total of 149 biospecimens collected of a possible 150. An additional 31st participant dropped out of the study shortly after informed consent due to relocation and is not included in the analyses. Participant characteristics and demographics are described in Table 1 . The participants were young, with average age of 23.4 years (SD = 3.8). Just over half the participants self-identified as Hispanic (53%), and over half of the participants were nulliparous (52% Table 2 . In samples collected at 7 to 10 weeks' GA, AMH was 36.7 pmol/L (SE = 8.1); at GA weeks 19 to 24, average AMH was 13.9 (SE = 2.0) pmol/L; and at weeks 34 to 37 was 9.5
(SE = 1.9) pmol/L. There was a statistically significant mean difference in AMH between samples collected at GA weeks 7 to 10 and those collected at weeks 11 to 14 by using Tukey post hoc tests (P < .05).
Substantial intraindividual and interindividual variabilities were FIGURE 1 Anti-Mϋllerian hormone (AMH; pmol/L) throughout pregnancy (mean and 95% CI). Anti-Müllerian hormone (pmol/L) means and 95% confidence intervals are shown by gestational age in weeks at blood sample collection. Means were significantly different by gestational age (P < .0001) in nonparametric comparisons of AMH by gestational age using Friedman test during gestation. 22 Other mechanisms may explain this observed trend, such as pregnancy-induced hemodilution with concurrent plasmaprotein binding increase and estrogen-induced AMH suppression during pregnancy. 24, 25 Given the observation of the most dramatic decreases in AMH very early in pregnancy, some women may have had a somewhat later initial visit than other women and provided samples too late in gestation to capture this very early gestational variation.
Prior studies of AMH in pregnancy have considered a mix of study samples and used different approaches. [17] [18] [19] [20] [21] 26 Using a cross-sectional approach among 84 women, no significant differences were observed in AMH levels compared among those in the first trimester (n = 27), in second trimester (n = 21), in the third trimester (n = 13), and a nonpregnant (n = 15) group. 18 In contrast, cross-sectional comparison of AMH levels among 554 women by trimester and postpartum suggested that levels decline over pregnancy and rapidly rise in the postpartum period. 26 Decreasing AMH has been observed in the first few weeks of gestation among women seeking fertility care (n = 85), 19 and declines in AMH have been observed late in pregnancy in a prospective study of women with and without GDM during the third trimester, with significant decreases between 28 to 32 and 34 to 36 weeks of gestation. gestation, AMH levels were observed to decline during the second and third trimesters of pregnancy. 21 Similarly, we observed a declining AMH throughout pregnancy independent of the age of the participant; through collection of 5 time points for biospecimen collection across pregnancy, we have described AMH trajectories in fine detail, both individually and as an overall trend. We observed somewhat larger changes in AMH in early pregnancy; however, declining mean AMH levels were observed throughout gestation.
Longitudinal assessment of AMH in gestation may provide insight into its role in folliculogenesis. Early pregnancy concentrations of AMH are thought to be similar to those before pregnancy. 19, 21 We observed high levels continuing to 10 weeks' gestation but rapid declines shortly thereafter, which may reflect the timing of ovarian function and follicular recruitment in pregnancy. 21 As AMH decreases in latter gestational ages, follicular recruitment declines, but the observation of continuing detectable levels suggests that the process is not halted completely in pregnancy. Likely, gonadotropin suppression during early pregnancy causes decreased AMH concentration and explains low concentrations of AMH from early pregnancy through postpartum. 27 Although our study characterized AMH in uncomplicated pregnancies, AMH has been suggested by some to be related to increased risk of adverse pregnancy outcomes, such as maternal hypertension or preeclampsia. 28, 29 Studies that assess AMH concentration prepregnancy, during gestation, and postpartum may help to better understand the mechanism of follicular recruitment and role of gonadotropin in AMH concentration in women who have completed pregnancy. Prospective pregnancy studies that evaluate maternal and pregnancy outcomes in addition to other biomarkers in pregnancy are important to better understand how AMH in pregnancy is related to these maternal and fetal characteristics.
Despite the small sample size, a strength of our study was the high level of compliance with the study protocol, which resulted in a large number of biospecimens across a wide range of gestation. Participants in the study provided all but 1 of the 5 scheduled biospecimen collections per participant, which helped us characterize within and Abbreviations: AMH, anti-Mϋllerian hormone; GA, gestational age; SE, standard error.
FIGURE 2
Trajectories of natural log transformed anti-Mϋllerian hormone (AMH) by gestational age. Natural log transformed AMH (pmol/L) is shown plotted by gestational age at sample collection for each cohort member. Mixed models of log AMH regressed on gestational age yielded the estimates shown in the plot along with the bold red regression line between-person AMH concentration variability. In addition, this supports the feasibility of longitudinal studies of biomarkers during pregnancy. Finally, eligibility for our study was relatively broad, contributing to the generalizability of our findings. We evaluated AMH with regard to race/ethnicity and other covariates and observed no associations, but because of the sample size (n = 30), the statistical power was low and these might have been missed.
| CONCLUSIONS
Our data suggest that, on average, AMH levels during gestation decrease but do not completely disappear and that patterns vary among women, particularly by baseline AMH levels. Additional studies may help improve understanding of the significance of AMH trajectories in gestation for pregnancy outcomes.
